Skip to main content
. Author manuscript; available in PMC: 2021 Oct 13.
Published in final edited form as: Surgery. 2019 Sep 24;167(1):233–240. doi: 10.1016/j.surg.2019.06.052

Fig 7.

Fig 7.

Treatment of ACC cells with 2.0 μM KU758 is associated with a 56% and 11% decrease in Axin2 levels in NCI-H295R and SW13 cells compared to control (DMSO only), respectively (P = .03 for NCI-H295R). KU758 treatment is associated with a 72% and 25% decrease in c-MET expression compared to control in NCI-H295R and SW13 cells, respectively (P < .01 for NCI-H295R). ACC, adrenocortical carcinoma.